Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWf:AgII) levels

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 387-393

  Vischer, Ulrich M ^a   Ingerslev, Jørgen ^b   Wollheim, Claes B ^a   Mestries, Jean Claude ^c   Tsakiris, Dimitrios A ^d   Haefeli, Walter E ^d   Kruithof, Egbert K O ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c CENTRE DE RECHERCHES   (France)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DESMOPRESSIN; FIBRIN; FIBRINOGEN; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SECRETION;

EID: 0031045129     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655973     Document Type: Article

References (36)

1. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
2. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
3. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-8.
4. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; I: 461-3.
5. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polack BCP, Donker AJM. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44: 561-4.
6. Gris JC, Branger B, Vecina F, al-Sabadani B, Fourcade J, Schved JF. Increased cardio-vascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-13.
7. Wagner DD. Cell biology of von Willebrand factor. Ann Rev Cell Biol 1990; 6: 217-46.
8. Sowie FJW, Solberg LA, Pass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest 1986; 78: 26-30.
9. Birch KA, Pober JS, Zavoico GB, Means AR, Ewenstein BM. Calcium/ calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothalial cells. J Cell Biol 1992; 118: 1501-10.
10. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-23.
11. 2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. J Clin Invest 1987; 79: 600-8.
12. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147-55.
13. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1976; 57: 1618-25.
14. Eyster ME, Ballard JO, Prager D. Comparison of factor VIII levels after adrenalin in classic hemophilia and von Willebrand's disease. Thromb Haemost 1978; 39: 657-62.
15. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital anad acquired bleeding disorders. Blood 1988; 72: 1449-55.
16. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Lab Clin Med 1987; 47: 143-9.
17. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-9.
18. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
19. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor multimers and unusually large vWf forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
20. Silveira AM, Elgue G, Hamsten A, Blomback M. von Willebrand factor in plasma and urine of men with premature coronary artery disease. Thromb Haemost 1992; 67: 161-5.
21. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
22. 2-macroglobulin and vonWillebrand factor possess covalently linked AB0 (H) blood group antigens in subjects with corresponding AB0 phenotype. Blood 1993; 82: 663-8.
23. Montgomery RR, Coller BS. von Willebrand disease. In: Coleman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3d Edition. Philadelphia: Lippincott Company 1994, p 134.
24. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization preceed the formation of Weibel-Palade bodies. Blood 1994; 83: 3536-44.
25. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci 1987; 84: 1955-9.
26. McCarroll DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand's antigen II and von Willebrand factor: discrimination between type I and Type II von Willebrand's disease. J Lab Clin Med 1984; 103: 704-11.
27. Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69: 27.
28. Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood 1993; 82: 1184.
29. Fay PJ, Smudzin TM. Topography of the human factor VIII-von Willebrand factor complex. J Biol Chem 1990; 265: 6197.
30. Vischer UM, Jornot L, Wollheim CB, Theler JM. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995; 85: 3164-72.
31. Tsakiris DA, Haefeli WE, Linder L, Steiner B, Marbet GA. Platelet surface activation markers after DDAVP infusion in healthy subjects. Thromb Haemost 1995; 74: 991-2.
32. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-90.
33. Ewenstein BM, Warhol MJ, Handin RI, Pober JS. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987; 104: 1423-33.
34. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-54.
35. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP140. J Biol Chem 1989; 264: 7768-71.
36. McCarroll DR, Ruggeri ZM, Montgomery RR. The effect of DDAVP on plasma levels of von Willebrand antigen II in normal individuals and patients with von Willebrand's disease. Blood 1984; 63: 532-5.